Gene Therapy Statistics in US 2026 | Key Facts, Treatments & Market Data

What Is Gene Therapy and Why Does It Matter in 2026?

Gene therapy is a class of medical treatment that alters part of a patient’s genome — through the replacement, deletion, or insertion of genetic material — to treat, prevent, or potentially cure disease at its biological root. Rather than managing symptoms with lifelong drugs, gene therapy aims to fix the underlying genetic defect itself, ideally with a single administration that delivers lasting or permanent benefit. The field spans several distinct approaches: in vivo therapy, in which the genetic material is delivered directly into the patient’s body using a viral or non-viral vector; ex vivo therapy, in which the patient’s own cells are extracted, genetically modified in the laboratory, and reinfused; and gene editing, in which tools like CRISPR-Cas9 directly cut and rewrite specific sequences of DNA within a patient’s cells. What all these approaches share is a fundamental ambition: to treat disease by intervening at the level of DNA itself, the code that governs how every cell in the human body functions. In the United States, the Food and Drug Administration (FDA) regulates gene therapies as biological products through its Center for Biologics Evaluation and Research (CBER), which created a dedicated Office of Therapeutic Products (OTP) specifically to oversee the growing field of cell and gene therapies.

In 2026, gene therapy has moved from theoretical promise into clinical reality at a pace that few in medicine predicted even a decade ago. The US is unambiguously the global leader in the field: North America accounts for more than 56% of the global gene therapy market by revenue, driven by its advanced healthcare infrastructure, the world’s most active FDA approval pipeline, and the deepest concentration of biotech innovation in the world. The US cell and gene therapy market was valued at $6.35 billion in 2024 and is projected to reach $51.15 billion by 2034, growing at a compound annual growth rate of 23.2%. More than 46 cell and gene therapy products have received FDA approval since the first approvals began, 1,300 active Investigational New Drug (IND) applications for gene therapies were on file with the OTP as of 2023–2024, and the FDA has set a target of approving 10 to 20 cell and gene therapies annually by 2025. This is no longer a research curiosity — it is one of the fastest-growing segments of American medicine, confronting diseases that have had no effective treatments for generations.

Interesting Key Facts About Gene Therapy in the US 2026

Source: Nova One Advisor US Cell and Gene Therapy Market report; IMARC Group Gene Therapy Market report; BioInformant FDA-approved cell and gene therapies tracker (November 2025); Cell & Gene/Cellandgene.com (February 2025); FDA CBER/OTP; NIH official Bespoke Gene Therapy Consortium press release; NIH/NINDS URGenT Network; NCATS official website; PMC/Nature published study (November 2023, doi:10.1038/s41434-023-00419-9); ASGCT-Citeline Q1 2025 Landscape Report; Trial Friend (March 29, 2026)

The key facts assembled here tell a story that simultaneously inspires and humbles. Gene therapy’s trajectory in the US has been extraordinary by any measure: from the first CAR-T approvals in 2017 and Zolgensma’s landmark SMA approval in 2019 to a 2024 in which eight novel cell and gene therapy products were approved in a single year, the pace of regulatory milestone has exceeded most early projections. The $6.35 billion US market in 2024 is expected to grow nearly eightfold to $51.15 billion by 2034 — a rate of compounding that reflects both the scientific pipeline and the growing willingness of payers, healthcare systems, and regulators to engage seriously with this class of medicine. The figure of 85% of rare diseases being single-gene disorders is not just a biological detail; it is the statement of a commercial and scientific opportunity. With 7,000 rare diseases identified and only a fraction currently treated, and with 30 million Americans living with rare conditions, gene therapy’s unfinished agenda is vast. The $76 million Bespoke Gene Therapy Consortium funded jointly by NIH and 15 private partners represents a recognition that the market alone will not address every disease — particularly those affecting the smallest patient populations — and that public-private collaboration is essential to push this field forward equitably.

FDA-Approved Gene Therapies in the US — Timeline and Key Products

Source: BioInformant FDA-approved US cell and gene therapies tracker, updated November 2025; FDA CBER Office of Therapeutic Products (OTP) approved products page; FDA press announcements (Casgevy December 2023; Zevaskyn April 2025); Cell & Gene report February 2025

The FDA approval timeline for gene therapies reads as a compressed history of one of medicine’s most transformative decades. The milestone of 2017 — when Kymriah, Yescarta, and Luxturna all received approval — marked the moment the field shifted from experimental to clinical reality. Each represented a different modality: Kymriah and Yescarta were CAR-T therapies reprogramming a patient’s own immune cells to hunt cancer, while Luxturna was a classic gene replacement therapy using an adeno-associated virus to deliver a working copy of a defective gene directly into retinal cells. Zolgensma’s 2019 approval for spinal muscular atrophy was a watershed: SMA had long been described as the leading genetic cause of infant mortality, and a single intravenous infusion of Zolgensma demonstrably allowed children who would previously not have survived past early childhood to walk, run, and develop normally. It also arrived as the most expensive drug ever approved at the time — $2.125 million per dose — setting a precedent that the entire field would wrestle with for years.

The December 8, 2023 approval of Casgevy — the world’s first medicine based on CRISPR-Cas9 gene-editing technology — deserves particular attention. CRISPR had won its inventors, Jennifer Doudna and Emmanuelle Charpentier, the 2020 Nobel Prize in Chemistry, and the journey from Nobel Prize to FDA approval took just three years — an almost unprecedented speed from fundamental scientific recognition to clinical translation. In clinical trials, Casgevy eliminated recurrent episodes of debilitating pain caused by sickle cell disease in 29 of 30 study participants. The FDA’s 2024 track record of 8 novel CGT approvals plus 6 new indications for existing therapies confirmed that the FDA’s stated target of approving 10–20 such therapies annually was not aspirational rhetoric but an achievable operational reality. The arrival of Tecelra in 2024 as the first-ever FDA-approved engineered T-cell receptor therapy added yet another mechanistic category to the approved portfolio, while Zevaskyn’s 2025 approval for epidermolysis bullosa wounds — administered as gene-modified cellular sheets rather than an infusion — demonstrated that the delivery forms of gene therapy continue to evolve well beyond anything the early pioneers of the field imagined.

Gene Therapy Diseases and Conditions Treated in the US 2026

Source: FDA CBER approved products; FDA press announcements; BioInformant (November 2025); NIH/NINDS URGenT; PMC/Nature study November 2023; Cell & Gene February 2025; CHOP press release (Casgevy December 2023); Drug Discovery Trends April 2024; ProPublica/CNN (Zolgensma SMA, June 2025); Trial Friend March 2026

The range of diseases now addressable by gene therapy in the US is a clinical landscape that would have been science fiction as recently as the early 2010s. The conditions span from cancers affecting tens of thousands to ultra-rare genetic disorders affecting fewer than 300 people globally — and the therapy modalities range from a one-time intravenous infusion to gene-modified cellular sheets applied to wounds to reprogrammed T-cells grown from a patient’s own blood. What unites all of them is the principle of targeting the genetic root cause rather than perpetually managing downstream symptoms. The story of SMA and Zolgensma illustrates this most vividly: the therapy reduced US death rates from SMA by two-thirds, not by suppressing symptoms or replacing lost muscle function, but by delivering a working copy of the SMN1 gene that infants with SMA lack. Children who would have died before their second birthday have instead learned to walk and run.

The breadth of cancer indications is particularly striking, with CAR-T therapies for B-cell cancers, T-cell lymphomas, multiple myeloma, and synovial sarcoma all now FDA-approved in the US. The projection that cancer patients will represent 48% of all gene therapy patients by 2034 reflects both the sheer scale of cancer as a disease category and the pace at which CAR-T and TCR therapies are accumulating approved indications. The cautionary tale of Skysona’s market failure — a legitimate FDA-approved gene therapy for a devastating pediatric brain disease that recorded zero commercial sales in its first quarter and was ultimately withdrawn from the US market in early 2025 — is equally important context. Having an approval is not the same as having a viable commercial product. The field is still learning how to price, pay for, deliver, and administer these therapies at scale — and those market realities are proving as challenging as the science itself.

Gene Therapy Costs and Pricing in the US 2026

Source: Trial Friend (March 29, 2026); ICER analyses cited in Managed Healthcare Executive and Drug Discovery Trends; ScienceInsights (November 2025); PMC/Nature study “The estimated annual financial impact of gene therapy in the United States” (published November 2023, doi:10.1038/s41434-023-00419-9); ProPublica/ProPublica-CNN (Zolgensma pricing, February/June 2025); PatentPC (February 2026); IMARC Group; Segal Consulting Q2 2024

The pricing structure of gene therapy in the US is unlike anything else in American medicine — and it has become one of the defining policy debates in healthcare economics. The logic that underpins these prices is not irrational on its own terms: a one-time cure for hemophilia B at $3.5 million is, over a lifetime, less costly than the $20+ million in factor replacement therapy a hemophilia patient would otherwise require. A $2.125 million Zolgensma dose for SMA is cheaper over a lifetime than $750,000 annually for Spinraza indefinitely. The Institute for Clinical and Economic Review (ICER), the US’s leading independent drug cost-effectiveness body, has consistently found that the clinical value of these therapies justifies multi-million-dollar price points — while simultaneously finding that the actual list prices often exceed even those elevated fair-value estimates. For Hemgenix, ICER found a fair value of $2.93–$2.96 million against a list price of $3.5 million. For Zolgensma, ICER estimated $900,000–$1.5 million against a list price of $2.125 million.

What makes these prices devastating in practice is the gap between how gene therapy’s value accrues (over decades, gradually) and how its cost falls (entirely upfront, immediately). Insurers who might pay a $3.5 million bill for a 40-year-old hemophilia patient know that patient may change insurers in the next year, leaving the prior payer with no future savings from having funded the cure. The market failures this creates are stark and documented: Roctavian for hemophilia A, priced at $2.9 million and FDA-approved, treated only five patients in a single quarter after launch. Skysona for cerebral adrenoleukodystrophy, also FDA-approved for a devastating pediatric brain disease, recorded zero commercial sales in Q1 2025 and was ultimately withdrawn from the market, with its manufacturer ending up in what amounted to a bankruptcy transaction that valued a company once worth $12 billion at approximately $49 million. The CMS Cell and Gene Therapy Access Model announced in late 2025 — which allows Medicaid to pay for gene therapies through outcomes-based arrangements tied to demonstrated results rather than full upfront payment — represents the most significant structural attempt yet to bridge this pricing gap in the public healthcare system.

Gene Therapy Clinical Pipeline and Research in the US 2026

Source: ASGCT-Citeline Gene, Cell & RNA Therapy Landscape Reports (Q1 and Q4 2025); Cell & Gene (February 2025); NIH/NCATS BGTC official page and press release; NIH/NINDS URGenT Network; PMC/Nature study (November 2023); Tufts Center for the Study of Drug Development 2022 study (cited in Applied Clinical Trials, 2025); Innovative Genomics Institute (July 2025); Grand View Research gene therapy platform market report; Applied Clinical Trials (2025)

The clinical pipeline for gene therapy in the US in 2026 is simultaneously its most promising and most pressurized aspect. The headline number — 3,483 gene, cell, and RNA therapies in development globally — understates how concentrated US leadership is in that figure. With 1,300 active INDs for gene therapies alone filed with the FDA’s OTP, the US regulatory system is processing one of the most complex and demanding approval pipelines in its history. The FDA’s commitment to approving 10–20 therapies annually requires a level of institutional capacity and scientific expertise that would have been unimaginable in the agency’s history even a decade ago. The OTP’s creation as a “super office” specifically dedicated to cell and gene therapy oversight is itself a structural acknowledgment of how fundamentally different the regulatory challenges of this modality are from those of small-molecule drugs or conventional biologics.

The NIH Bespoke Gene Therapy Consortium (BGTC) represents a particularly important model for the ultra-rare disease end of the pipeline. Many diseases with identified genetic causes and known patient populations simply cannot attract commercial development: the market is too small, the clinical trial design too complex, and the return on investment too uncertain. By creating a shared platform — standardized AAV vectors, common manufacturing methods, harmonized regulatory approaches — the BGTC aims to industrialize the development of gene therapies for conditions where no pharmaceutical company will otherwise go. The extraordinary 2025 case of a personalized CRISPR therapy designed and delivered to a single infant in just six months points toward a future where truly individualized gene therapy — bespoke to a single patient’s unique mutation — becomes clinically feasible. The $557.1 million in start-up financing across 14 transactions in Q4 2025 alone suggests the investment community still sees transformational value in the space, even as average ROI for marketed rare disease therapies has fallen to 2.5% — a level that will force a reckoning with the sustainability of the current commercial model.

Gene Therapy by Delivery Method and Technology in the US 2026

Source: IMARC Group gene therapy market report; Grand View Research gene therapy platform market report; Nova One Advisor US cell and gene therapy market report; Cell & Gene / ASGCT-Citeline Q1 2025 Landscape Report; FDA CBER OTP approved products; Innovative Genomics Institute CRISPR clinical trials update (July 2025)

The technology landscape of gene therapy delivery is itself a field in rapid evolution, and the choice of delivery method has profound consequences for which diseases can be treated, how safely, at what cost, and with what durability. AAV (adeno-associated virus) remains the dominant platform for in vivo gene delivery precisely because it has the safety profile that regulators and patients need: it does not integrate into the genome (reducing cancer risk), it is relatively non-immunogenic (the body’s immune system mounts a milder reaction to it than to most other vectors), and it can be engineered to target specific tissues — with different AAV serotypes having affinities for the liver, the eye, the brain, and the muscle. Zolgensma, Luxturna, Hemgenix, Elevidys, and Kebilidi are all AAV-based therapies, and the AAV platform’s dominance in the approved portfolio reflects decades of safety accumulation in human clinical trials.

CRISPR is the technology that generates the most excitement — and the most uncertainty. Casgevy’s approval proved that CRISPR can safely edit human cells at scale and deliver dramatic clinical benefits. But the December 2023 approval also came with important caveats: the FDA required 15 years of patient follow-up to monitor for off-target editing effects and potential long-term cancer risk. Most trial participants had been followed for less than two years at the time of approval. The field of base editing — which makes precise single-letter DNA changes without cutting both strands of the double helix (the cut being a theoretical source of off-target risk) — is in early clinical trials and may eventually offer a safer precision alternative to standard CRISPR-Cas9 for specific applications. Meanwhile, mRNA-based in vivo delivery via lipid nanoparticles — the same technology platform validated by COVID-19 vaccines — is advancing rapidly for oncology and cardiovascular applications, with no approved US gene therapy products yet but a robust pipeline that many expect to yield approvals within the next several years.

Gene Therapy Market Leaders and Investment in the US 2026

Source: BioInformant (November 2025); Cell & Gene (January and February 2025); Drug Discovery Trends (April 2024); Trial Friend (March 2026); NIH BGTC official; ProPublica/CNN (Zolgensma, 2025); FDA CBER; ASGCT-Citeline Q4 2025

The investment and competitive landscape of gene therapy in the US in 2026 reflects the maturation of a field that began with academic pioneers and small biotechs and has now been absorbed into the strategic core of the world’s largest pharmaceutical companies. Eli Lilly’s $700 million Boston Innovation Center dedicated to gene therapy signals that the company most famous for Mounjaro is placing a serious long-term bet on genetic medicine. Novartis’s $1.1 billion acquisition of Kate Therapeutics in 2024 — following its earlier $8.7 billion acquisition of AveXis (which held Zolgensma) — confirms that the Swiss giant sees gene therapy as a multi-decade strategic platform rather than a one-time product bet. Pfizer’s entry into the hemophilia gene therapy market with Beqvez directly competing against CSL Behring’s Hemgenix shows that blockbuster-era companies are now fighting for position in patient populations that were previously served only by specialist biotechs.

The creation of the CMS Cell and Gene Therapy Access Model in late 2025 may prove to be the most consequential single development for the long-term trajectory of the US gene therapy market. By creating a formal Medicaid payment structure based on outcomes — paying less if a therapy fails and more if it succeeds over time — CMS has provided a template that could unblock access for the approximately 80 million Americans on Medicaid who currently face the most severe barriers to high-cost gene therapy access. The contrast between the commercial and the public health dimensions of this field has never been sharper: the science has advanced to the point where a single infant can receive a personalized CRISPR therapy designed specifically for their mutation in six months, while tens of thousands of Americans who could benefit from existing approved therapies cannot access them due to price, insurance denials, or the simple absence of a qualified treatment center within reach. Gene therapy in 2026 is a field that has solved many of its hardest scientific problems and now faces its hardest human ones.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE